|
|
|
|
|
|
|
Cancer Lett 2010,Sep,28;295(2):205-13; (PMID: 20356671)
BRCA1 is a tumor-suppressor gene responsible for hereditary breast and ovarian cancers. Characterization of alternately spliced forms of [...]
|
|
|
Biochem Pharmacol 2010,Sep,01;80(5):647-53; (PMID: 20510205)
[...]Here we review the use of BRCA1 as a marker of response to therapy with a particular focus on the use of Cisplatin and PARP inhibitors. We also explore the use of BRCA1 as a marker of response to [...]
|
|
|
J Cancer Res Clin Oncol 2010,Sep,01;136(9):1407-14; (PMID: 20127252)
[...] proteins was measured by Western blotting, while the expression of TERT, KU70, and BRCA1 proteins was detected using the immunohistochemical method. The mean telomere length was determined by Southern blotting[...]
|
|
|
Int J Cancer 2010,Aug,01;127(3):589-97; (PMID: 19950226)
[...]To test this notion, frequency of single nucleotide polymorphisms (SNPs; n = 42) within predicted miRNA binding sites or miRNA precursors were determined and compared in 363 BRCA1 mutation carriers: asymptomatic (n = 160), breast cancer (n = 140) and ovarian cancer (n = 63) [...]
|
|
|
J Pathol 2010,Aug,01;221(4):452-61; (PMID: 20593485)
[...]breast tumours from cases carrying a BRCA1, BRCA2 or ATM mutation, or from non-BRCA1/2 families. We found that replicate samples correlated well with each other (r(2) = 0.9-0.98). In 12/15 cases, the matched [...]
|
|
|
Tumour Biol 2010,Aug,01;31(4):321-31; (PMID: 20490964)
[...]The methylation frequency of ten genes in serum of 50 SBCs varied from 10% in FHIT to 74% in RASSF1A. The methylation status of RASSF1A, BRCA1, p16, CDH1, ER, RARbeta2, APC, and DAPK was significantly correlated with [...]
|
|
|
Hum Mol Genet 2010,Aug,01;19(15):3021-9; (PMID: 20484223)
[...]Hence, the phenotype of the Palb2((-/-)) mice in many regards resembles those previously reported for Brca1 and Brca2 knockout mice. The similarity in the phenotypes between Palb2, Brca1 and Brca2[...]
|
|
|
Breast Cancer Res Treat 2010,Aug,01;122(3):733-43; (PMID: 19894111)
[...]Large genomic rearrangements are estimated to account for approximately 5-10% of all disease-causing mutations in BRCA1 and BRCA2 genes in patients with hereditary breast and ovarian cancer syndrome (HBOC). We use MRC-Holland Multiplex Ligation-dependent Probe [...]
|
|
|
Breast Cancer Res Treat 2010,Aug,01;122(3):721-31; (PMID: 19882246)
Expression profiling of BRCA1-deficient tumours has identified a pattern of gene expression similar to basal-like breast tumours.[...]
|
|
|
Gynecol Endocrinol 2010,Aug,01;26(8):568-77; (PMID: 20632911)
BRCA1 and BRCA2 mutation carriers have a 54-85% and 45% lifetime risk of developing breast cancer[...]
|
 1 2 3 4 5 6 7 8 
|
|
|
|
|
